FLUBLOK® to be distributed by Avanzcare in the MENA region.

FLUBLOK® to be distributed by Avanzcare in the MENA region.


Flublok, produced by Protein Sciences and distributed by Avanzcare in the MENA region, is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. The vaccine was approved by the FDA in January 2013.
Flublok is highly purified and does not contain any preservatives (e.g. thimerosal, a mercury derivative), egg proteins, gelatin or latex. 
In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein)*.  
Flublok is a perfect copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness. *
Flublok demonstrated a higher antibody response in the A strains during 2 clinical trials in adults ≥ 50 years old. The B strain antibody response was comparable to traditional trivalent vaccines.

Indication: Flublok® is approved for people 18 and older to prevent influenza disease.
Safety information: The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur. Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Clinical effectiveness in adults 50 and older is based on the immune response elicited by Flublok and not on demonstration of decreased influenza disease. Please see the complete Package Insert available at www.flublok.com .

* Skowronski et al. (2014) PLOS ONE 9(3), e92153

close button
;